Kazia治疗机构在筹集了50M美元、满足了股本要求和确保了继续交易后,恢复了对Nasdaq的遵守。 Kazia Therapeutics regained Nasdaq compliance after raising $50M, meeting equity requirements and securing continued trading.

在筹集了5 000万美元的股本融资,满足了250万美元的股东最低股本要求之后,Kazia治疗公司重新遵守了Nasdaq上市规则。 Kazia Therapeutics has regained compliance with Nasdaq listing rules after raising $50 million in equity financing, meeting the $2.5 million minimum stockholders’ equity requirement. 该公司作为KZIA进行交易,于2025年12月18日收到Nasdaq的确认,允许其股票继续在Nasdaq资本市场上进行交易。 The company, which trades as KZIA, received confirmation from Nasdaq on December 18, 2025, allowing its shares to continue trading on the Nasdaq Capital Market. 财政刺激支持正在进行的帕萨利西布临床发展,帕萨利西布是一种正在接受脑癌和乳癌高级测试的药物。 The financial boost supports ongoing clinical development of paxalisib, a drug being tested for brain cancers and advanced breast cancer. 该公司表示,财务状况的改善增强了投资者的信心和灵活性。 The company said the improved financial standing enhances investor confidence and flexibility. 前瞻性声明包括与临床试验、监管批准和市场条件有关的风险。 Forward-looking statements include risks related to clinical trials, regulatory approval, and market conditions.